Committee (IACUC) in the local interpretation and application of the law. is responsible for establishing guidelines and policies regulating animal use. reviewing protocols with surgical components. anesthesia/analgesia selection, and post-operative care and analgesia.
AYou will receive treatment with OPDIVO in a hospital or clinic, under the supervision of an experienced doctor. OPDIVO will be given to you as an infusion (a drip) into a vein (intravenously) over a period of 60 minutes, every 2 weeks.
The most frequent serious adverse events with OPDIVO in combination with ipilimumab, as compared to single-agent ipilimumab, were colitis (17% vs. 9%), diarrhea (9% vs. 7%), pyrexia (6% vs. 7%), and pneumonitis (5% vs. 0).